ME
23andMe Holding Co. [ME] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ME Stock Summary
Top 10 Correlated ETFs
ME
Top 10 Correlated Stocks
ME
In the News
ME Financial details
Company Rating
Neutral
Market Cap
214.03M
Income
-521.97M
Revenue
247.99M
Book val./share
0.78
Cash/share
0.5
Dividend
-
Dividend %
-
Employees
769
Optionable
No
Shortable
Yes
Earnings
26 May 2024
P/E
-1.16
Forward P/E
-
PEG
-0.14
P/S
1.45
P/B
0.62
P/C
1.12
P/FCF
-2.49
Quick Ratio
2.54
Current Ratio
2.93
Debt / Equity
0.21
LT Debt / Equity
0.19
-
-
EPS (TTM)
-1.11
EPS next Y
-
EPS next Q
-
EPS this Y
15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
8.92%
Revenue last 5Y
-7.44%
Revenue Q/Q
-10.5%
EPS Q/Q
262.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
21.43%
Inst Trans
0.74%
ROA
-42%
ROE
-49%
ROC
-0.51%
Gross Margin
46%
Oper. Margin
-131%
Profit Margin
-124%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.401-2.3
52W High
-
52W Low
-
RSI
55
Rel Volume
0.22
Avg Volume
6.66M
Volume
1.44M
Perf Week
21.64%
Perf Month
4.95%
Perf Quarter
-27%
Perf Half Y
-36.57%
-
-
-
-
Beta
1.277
-
-
Volatility
0.07%, 0.05%
Prev Close
11.08%
Price
0.5615
Change
19.27%
ME Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.08 | 0.75 | 0.6 | 0.75 | 0.66 | |
| Net income per share | -0.45 | -0.71 | -0.45 | -0.6 | -0.69 | |
| Operating cash flow per share | -0.24 | -0.46 | -0.18 | -0.46 | -0.37 | |
| Free cash flow per share | -0.31 | -0.64 | -0.2 | -0.5 | -0.39 | |
| Cash per share | 1.11 | 0.52 | 0.7 | 1.53 | 0.86 | |
| Book value per share | 0.77 | 0.33 | -1.47 | 2.53 | 1.58 | |
| Tangible book value per share | 0.77 | 0.32 | -1.48 | 1.33 | 0.67 | |
| Share holders equity per share | 0.77 | 0.33 | -1.47 | 2.53 | 1.58 | |
| Interest debt per share | 0 | 0.02 | 0.23 | 0.24 | 0.17 | |
| Market cap | 3.98B | 3.98B | 4.13B | 1.38B | 1.03B | |
| Enterprise value | 3.53B | 3.86B | 3.94B | 917.78M | 727.88M | |
| P/E ratio | -21.7 | -13.77 | -22.54 | -6.37 | -3.3 | |
| Price to sales ratio | 9.03 | 13.04 | 16.95 | 5.09 | 3.44 | |
| POCF ratio | -40.59 | -21.44 | -55.67 | -8.3 | -6.22 | |
| PFCF ratio | -31.62 | -15.36 | -50.64 | -7.66 | -5.83 | |
| P/B Ratio | 12.69 | 29.68 | -6.94 | 1.51 | 1.44 | |
| PTB ratio | 12.69 | 29.68 | -6.94 | 1.51 | 1.44 | |
| EV to sales | 8.01 | 12.65 | 16.17 | 3.38 | 2.43 | |
| Enterprise value over EBITDA | -19.74 | -26.51 | -23.91 | -3.52 | -2.53 | |
| EV to operating cash flow | -35.98 | -20.8 | -53.13 | -5.5 | -4.4 | |
| EV to free cash flow | -28.03 | -14.9 | -48.33 | -5.08 | -4.12 | |
| Earnings yield | -0.05 | -0.07 | -0.04 | -0.16 | -0.3 | |
| Free cash flow yield | -0.03 | -0.07 | -0.02 | -0.13 | -0.17 | |
| Debt to equity | 0 | 0.06 | -0.16 | 0.09 | 0.12 | |
| Debt to assets | 0 | 0.02 | 0.21 | 0.07 | 0.09 | |
| Net debt to EBITDA | 2.53 | 0.82 | 1.14 | 1.79 | 1.05 | |
| Current ratio | 2.75 | 1.76 | 2.58 | 3.93 | 2.84 | |
| Interest coverage | 0 | 0 | 0 | -917.52 | 33.81 | |
| Income quality | 0.53 | 0.74 | 0.4 | 0.77 | 0.53 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.11 | 0.19 | 0.41 | 0.36 | 0.39 | |
| Research and developement to revenue | 0.32 | 0.59 | 0.66 | 0.7 | 0.74 | |
| Intangibles to total assets | 0 | 0.01 | 0.02 | 0.38 | 0.44 | |
| Capex to operating cash flow | 0.28 | 0.4 | 0.1 | 0.08 | 0.07 | |
| Capex to revenue | -0.06 | -0.24 | -0.03 | -0.05 | -0.04 | |
| Capex to depreciation | -2.81 | -3.16 | -0.36 | -0.53 | -0.31 | |
| Stock based compensation to revenue | 0.09 | 0.15 | 0.36 | 0.21 | 0.39 | |
| Graham number | 2.8 | 2.3 | 3.86 | 5.86 | 4.96 | |
| ROIC | -0.6 | -1.1 | 0.45 | -0.23 | -0.36 | |
| Return on tangible assets | -0.26 | -0.72 | -0.41 | -0.3 | -0.59 | |
| Graham Net | 0.21 | -0.12 | -1.87 | 0.9 | 0.36 | |
| Working capital | 327.11M | 106.43M | 191.96M | 448.55M | 275.58M | |
| Tangible asset value | 313.29M | 128.78M | -602.51M | 480.37M | 301.01M | |
| Net current asset value | 131.09M | -24.55M | -734.14M | 365.38M | 196.33M | |
| Invested capital | 0 | 0.06 | -0.16 | 0.09 | 0.12 | |
| Average receivables | 0 | 8.5M | 4.44M | 2.93M | 2.64M | |
| Average payables | 0 | 29.38M | 12.68M | 25.1M | 25.43M | |
| Average inventory | 0 | 13.9M | 10.18M | 8.51M | 10.52M | |
| Days sales outstanding | 8.77 | 7.64 | 3.71 | 4.54 | 2.31 | |
| Days payables outstanding | 64.64 | 28.42 | 35.29 | 99.64 | 28.59 | |
| Days of inventory on hand | 19.36 | 30.68 | 17.94 | 28.34 | 22.67 | |
| Receivables turnover | 41.6 | 47.79 | 98.32 | 80.44 | 157.88 | |
| Payables turnover | 5.65 | 12.84 | 10.34 | 3.66 | 12.77 | |
| Inventory turnover | 18.85 | 11.9 | 20.34 | 12.88 | 16.1 | |
| ROE | -0.58 | -2.16 | 0.31 | -0.24 | -0.44 | |
| Capex per share | -0.07 | -0.18 | -0.02 | -0.04 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.15 | 0.2 | 0.13 | 0.11 | 0.09 | |
| Net income per share | -0.2 | -0.14 | -0.23 | -0.16 | -0.58 | |
| Operating cash flow per share | 0.06 | -0.1 | -0.15 | -0.12 | -0.03 | |
| Free cash flow per share | 0.05 | -0.11 | -0.16 | -0.13 | -0.03 | |
| Cash per share | 0.95 | 0.85 | 0.68 | 0.54 | 0.5 | |
| Book value per share | 1.66 | 1.56 | 1.46 | 1.32 | 0.78 | |
| Tangible book value per share | 0.74 | 0.66 | 0.57 | 0.46 | 0.35 | |
| Share holders equity per share | 1.66 | 1.56 | 1.46 | 1.32 | 0.78 | |
| Interest debt per share | 0.18 | 0.18 | 0.18 | 0.17 | 0.16 | |
| Market cap | 979.36M | 1.04B | 808.95M | 464.27M | 439.22M | |
| Enterprise value | 626.16M | 738.72M | 577.83M | 288.93M | 275.62M | |
| P/E ratio | -2.66 | -4.06 | -1.93 | -1.54 | -0.4 | |
| Price to sales ratio | 14.63 | 11.26 | 13.29 | 9.29 | 9.82 | |
| POCF ratio | 38.34 | -23.14 | -11.66 | -8.13 | -36.42 | |
| PFCF ratio | 43.56 | -21.56 | -11.23 | -7.75 | -31.21 | |
| P/B Ratio | 1.3 | 1.46 | 1.2 | 0.74 | 1.16 | |
| PTB ratio | 1.3 | 1.46 | 1.2 | 0.74 | 1.16 | |
| EV to sales | 9.35 | 8 | 9.49 | 5.78 | 6.16 | |
| Enterprise value over EBITDA | -6.45 | -12.13 | -6.23 | -4.4 | 2.18 | |
| EV to operating cash flow | 24.51 | -16.43 | -8.33 | -5.06 | -22.85 | |
| EV to free cash flow | 27.85 | -15.31 | -8.02 | -4.82 | -19.58 | |
| Earnings yield | -0.09 | -0.06 | -0.13 | -0.16 | -0.63 | |
| Free cash flow yield | 0.02 | -0.05 | -0.09 | -0.13 | -0.03 | |
| Debt to equity | 0.11 | 0.12 | 0.12 | 0.13 | 0.21 | |
| Debt to assets | 0.08 | 0.09 | 0.1 | 0.1 | 0.13 | |
| Net debt to EBITDA | 3.64 | 4.95 | 2.49 | 2.67 | -1.29 | |
| Current ratio | 2.54 | 2.84 | 3.03 | 2.93 | 2.15 | |
| Interest coverage | -79.2 | 15.25 | 0 | 0 | 0 | |
| Income quality | -0.28 | 0.7 | 0.66 | 0.76 | 0.04 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.46 | 0.29 | 0.91 | 0.6 | 0.79 | |
| Research and developement to revenue | 0.86 | 0.66 | 1.02 | 1.09 | 0.93 | |
| Intangibles to total assets | 0.4 | 0.44 | 0.47 | 0.51 | 0.34 | |
| Capex to operating cash flow | -0.12 | 0.07 | 0.04 | 0.05 | 0.17 | |
| Capex to revenue | -0.05 | -0.04 | -0.04 | -0.06 | -0.04 | |
| Capex to depreciation | -0.33 | -0.39 | -0.33 | -0.34 | -0.28 | |
| Stock based compensation to revenue | 0.51 | 0.24 | 0.84 | 0.47 | 0.59 | |
| Graham number | 2.75 | 2.22 | 2.73 | 2.17 | 3.19 | |
| ROIC | -0.11 | -0.08 | -0.13 | -0.1 | -0.53 | |
| Return on tangible assets | -0.15 | -0.12 | -0.23 | -0.19 | -0.69 | |
| Graham Net | 0.41 | 0.36 | 0.28 | 0.19 | 0.08 | |
| Working capital | 308.56M | 275.58M | 241.37M | 196.39M | 165.82M | |
| Tangible asset value | 336.06M | 301.01M | 264.19M | 216.7M | 169.18M | |
| Net current asset value | 235.01M | 196.33M | 164.57M | 122.02M | 78.94M | |
| Invested capital | 0.11 | 0.12 | 0.12 | 0.13 | 0.21 | |
| Average receivables | 39.85M | 14.35M | 3.01M | 2.81M | 12.76M | |
| Average payables | 12.27M | 13.45M | 12.84M | 10.65M | 10.86M | |
| Average inventory | 12.88M | 11.1M | 11.03M | 13.4M | 15.32M | |
| Days sales outstanding | 36.04 | 1.85 | 6.1 | 2.7 | 48.31 | |
| Days payables outstanding | 34.78 | 22.2 | 38.01 | 27.21 | 47.76 | |
| Days of inventory on hand | 29.74 | 17.6 | 35.23 | 47.69 | 56.83 | |
| Receivables turnover | 2.5 | 48.7 | 14.76 | 33.31 | 1.86 | |
| Payables turnover | 2.59 | 4.05 | 2.37 | 3.31 | 1.88 | |
| Inventory turnover | 3.03 | 5.11 | 2.55 | 1.89 | 1.58 | |
| ROE | -0.12 | -0.09 | -0.15 | -0.12 | -0.74 | |
| Capex per share | -0.01 | -0.01 | -0.01 | -0.01 | 0 |
ME Frequently Asked Questions
What is 23andMe Holding Co. stock symbol ?
23andMe Holding Co. is a US stock , located in South san francisco of Ca and trading under the symbol ME
What is 23andMe Holding Co. stock quote today ?
23andMe Holding Co. stock price is $0.5615 today.
Is 23andMe Holding Co. stock public?
Yes, 23andMe Holding Co. is a publicly traded company.
Company Profile
- Volume Average 6.66M
- Market Capitalization 214.03M
- Employee 769
- CEO Ms. Anne Wojcicki
- Headquarters South San Francisco,CA,US
- IPO Date 2020-11-23
-
Website
https://www.23andme.com 
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
